C

Champions Oncology, Inc.

XNAS · Laboratory Analytical Instruments · S&P 500

$6.10

$0.00 (0.00%) today

Open $6.10 High $6.15 Low $6.10 Vol 2K Avg $6.12

Related Stocks

Find similar stocks by technical condition — S&P 500 universe

Symbol Company Name Exchange Currency Category
LIMN Liminatus Pharma, Inc. Class A Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CMPX Compass Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
EXOZ eXoZymes Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PHGE BiomX Inc. XASE USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SANA Sana Biotechnology, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SGMO Sangamo Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PCVX Vaxcyte, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
TECH Bio-Techne Corp. XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CELZ Creative Medical Technology Holdings, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
MGTX MeiraGTx Holdings plc Ordinary Shares XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

52-week price range

$0.00 $0.00

Price is 0.0% above its 52-week low and 0.0% below its 52-week high. Trading in the lower half of its annual range — closer to the floor than the ceiling.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

  • Primary Exchange: XNAS
  • Market Cap: 83598692.52
  • Address:
  • Category: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
  • Total Employees: 306
  • Listing Date: 1994-10-31